Unknown

Dataset Information

Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.


ABSTRACT: Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are treated with targeted therapies based on clinical features: low-risk patients are usually treated with anti-angiogenic drugs and intermediate/high-risk patients with immune therapy. However, there are no biomarkers available to guide treatment choice for these patients. A recently published phase II clinical trial observed a correlation between ccRCC patients' clustering and their response to targeted therapy. However, the clustering of these groups was not distinct. Here, we analyzed the gene expression profile of 469 ccRCC patients, using featured selection technique, and have developed a refined 66-gene signature for

SUBMITTER: D'Costa NM 

PROVIDER: S-EPMC7005147 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature